Compare Aurobindo Pharma with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SANOFI INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SANOFI INDIA AUROBINDO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 18.1 42.5 42.6% View Chart
P/BV x 3.9 8.6 45.2% View Chart
Dividend Yield % 0.3 1.0 26.7%  

Financials

 AUROBINDO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SANOFI INDIA
Dec-18
AUROBINDO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8306,840 12.1%   
Low Rs5274,630 11.4%   
Sales per share (Unadj.) Rs333.91,203.1 27.8%  
Earnings per share (Unadj.) Rs40.4165.3 24.4%  
Cash flow per share (Unadj.) Rs51.8209.9 24.7%  
Dividends per share (Unadj.) Rs2.5084.00 3.0%  
Dividend yield (eoy) %0.41.5 25.2%  
Book value per share (Unadj.) Rs237.1963.6 24.6%  
Shares outstanding (eoy) m585.9123.03 2,544.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.8 42.6%   
Avg P/E ratio x16.834.7 48.5%  
P/CF ratio (eoy) x13.127.3 48.0%  
Price / Book Value ratio x2.96.0 48.1%  
Dividend payout %6.250.8 12.2%   
Avg Mkt Cap Rs m397,569132,078 301.0%   
No. of employees `00017.93.3 540.9%   
Total wages/salary Rs m25,8494,068 635.4%   
Avg. sales/employee Rs Th10,956.98,393.8 130.5%   
Avg. wages/employee Rs Th1,447.71,232.4 117.5%   
Avg. net profit/employee Rs Th1,324.31,153.0 114.9%   
INCOME DATA
Net Sales Rs m195,63627,708 706.1%  
Other income Rs m1,553897 173.2%   
Total revenues Rs m197,18928,605 689.4%   
Gross profit Rs m39,5196,235 633.8%  
Depreciation Rs m6,6801,027 650.4%   
Interest Rs m2,6267 37,514.3%   
Profit before tax Rs m31,7676,098 520.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,292 317.1%   
Profit after tax Rs m23,6453,806 621.3%  
Gross profit margin %20.222.5 89.8%  
Effective tax rate %22.937.6 60.9%   
Net profit margin %12.113.7 88.0%  
BALANCE SHEET DATA
Current assets Rs m153,64515,922 965.0%   
Current liabilities Rs m120,4296,235 1,931.5%   
Net working cap to sales %17.035.0 48.6%  
Current ratio x1.32.6 50.0%  
Inventory Days Days13564 212.4%  
Debtors Days Days6421 305.2%  
Net fixed assets Rs m103,9097,539 1,378.3%   
Share capital Rs m586230 254.7%   
"Free" reserves Rs m138,32221,962 629.8%   
Net worth Rs m138,90822,192 625.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54429,839 886.6%  
Interest coverage x13.1872.1 1.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 79.6%   
Return on assets %9.912.8 77.7%  
Return on equity %17.017.2 99.3%  
Return on capital %23.827.5 86.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3167,587 1,282.7%   
Fx outflow Rs m40,5897,145 568.1%   
Net fx Rs m56,727442 12,834.2%   
CASH FLOW
From Operations Rs m16,2203,739 433.8%  
From Investments Rs m-28,768-731 3,935.5%  
From Financial Activity Rs m19,191-1,972 -973.2%  
Net Cashflow Rs m6,6561,036 642.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.0 14.4 55.2%  
FIIs % 27.7 14.6 189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 15,184 458.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA  NOVARTIS  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens above 50,000-Mark; Tata Motors & Bajaj Finance Top Gainers(09:30 am)

Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 21, 2021 11:26 AM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS